0001013762-23-000785.txt : 20231003 0001013762-23-000785.hdr.sgml : 20231003 20231003095137 ACCESSION NUMBER: 0001013762-23-000785 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230927 FILED AS OF DATE: 20231003 DATE AS OF CHANGE: 20231003 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mathias Sheila CENTRAL INDEX KEY: 0001991182 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40064 FILM NUMBER: 231301788 MAIL ADDRESS: STREET 1: 1055 WESTLAKES DRIVE STREET 2: SUITE 300 CITY: BERWYN STATE: PA ZIP: 19312 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Virpax Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001708331 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821510982 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1055 WESTLAKES DRIVE, SUITE 300 CITY: BERWYN STATE: PA ZIP: 19312 BUSINESS PHONE: 610-727-4597 MAIL ADDRESS: STREET 1: 1055 WESTLAKES DRIVE, SUITE 300 CITY: BERWYN STATE: PA ZIP: 19312 FORMER COMPANY: FORMER CONFORMED NAME: Virpax Pharmaceuticals Inc. DATE OF NAME CHANGE: 20170602 3 1 ownership.xml X0206 3 2023-09-27 0 0001708331 Virpax Pharmaceuticals, Inc. VRPX 0001991182 Mathias Sheila 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 0 1 0 0 Chief Scientific Officer Stock Option (Right to buy) 4.62 2022-04-07 2031-04-06 Common Stock 25000 D Stock Option (Right to buy) 2.13 2023-01-31 2032-01-30 Common Stock 60676 D Stock Option (Right to buy) 0.79 2024-01-25 2033-01-24 Common Stock 112000 D These options vest pro rata equally over three years. Exhibit 24 - Power of Attorney /s/ Sheila Mathias 2023-10-03 EX-24 2 ea186192-ex24_virpax.htm POWER OF ATTORNEY

Exhibit 24

 

POWER OF ATTORNEY

 

Know all by these present that the undersigned hereby constitutes and appoints each of Anthony P. Mack and/or Jeff Gudin their true and lawful attorney-in-fact to:

 

1. execute for and on behalf of the undersigned Schedules 13D and 13G, Form ID, and Forms 3, 4 and 5 in accordance with Sections 13 and 16(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and the rules thereunder;

 

2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete the execution of any such Schedules 13D or 13G, Form ID application for EDGAR codes, and Forms 3, 4 or 5, and the timely filing of such Forms with the United States Securities and Exchange Commission and any other authority; and

 

3. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, including, without limitation, the execution and filing of a Form 4 with respect to a transaction which may be reported on a Form 5, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion.

 

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as he might or could do in person, with full power of substitution and resubstitution, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned’s responsibilities to comply with Sections 13 and 16 of the Exchange Act.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any Schedules 13D and 13G and Forms 3, 4 and 5 in accordance with Sections 13 and 16(a) of the Exchange Act and the rules thereunder with respect to the undersigned’s holdings of and transactions in securities issued by Virpax Pharmaceuticals, Inc., its predecessors or assigns, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of August 8, 2023.

 

  /s/ Sheila Mathias
  By: Sheila Mathias